Findings

What do systematic reviews say?

3 questions · 3 findings · 3 reviews · Oral medicine and oral cancer

Sort:Best matchNewest Highest certainty Download CSV

No studies found 3 · 100%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 0 · 0%

Antioxidants (lycopene, curcumin, Oxitard) vs Placebo or no active treatment

Economic: direct costs · People of any age with a confirmed diagnosis, by clinical examination and biopsy, of oral submucous fibrosis (OSF)

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for managing oral submucous fibrosis 2024 · Cochrane All outcomes
The trials did not measure costs.
0 studies
No studies found

Systemic oral acyclovir vs placebo or no treatment

Direct costs (medication, hospital bed days) · Children and young adults under 25 years with primary herpetic gingivostomatitis (with or without herpes labialis)

The review found no eligible studies for this question.

1 finding from 1 review

Acyclovir for treating primary herpetic gingivostomatitis 2008 · Cochrane All outcomes
No data available in either included study.
Studies not reported
No studies found

EGFR monoclonal antibody (cetuximab or nimotuzumab) plus standard therapy (radiotherapy or chemoradiotherapy) vs Standard therapy alone (radiotherapy or chemoradiotherapy)

Costs (direct and indirect) · People with squamous cell carcinoma of the oral cavity or oropharynx

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy 2015 · Cochrane All outcomes
24 to 70 months
No included studies addressed direct and indirect costs to participants and health services (review-wide gap).
0 studies
No studies found